Pipeline Therapeutics Announces Participation in Upcoming Investor Conferences in November 2022

SAN DIEGO--(BUSINESS WIRE)-- Pipeline Therapeutics, a clinical-stage biopharmaceutical company pioneering precision neuroregeneration, announced today that management will present at the following investor conferences during November 2022:

• Guggenheim 4^th Annual Immunology and Neurology Day, November 14-15, in New York, NY
• Stifel Healthcare Conference, November 15-16, in New York, NY

About Pipeline Therapeutics

Pipeline Therapeutics is a clinical-stage biopharmaceutical company pioneering the development and commercialization of first-in-class therapies for precision neuroregeneration including myelin restoration, synaptogenesis and axonal repair. The Company has a broad pipeline of programs to address multiple CNS disorders. Its flagship program, PIPE-307, has completed two Phase 1 clinical trials - a SAD/MAD study and a PET study - in healthy volunteers, and has received Investigational New Drug clearance from the Food and Drug Administration to initiate clinical development in relapsing-remitting MS patients.

For more information, please visit www.pipelinetherapeutics.com and engage with us on LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221101006161/en/